Tirzepatide

Tirzepatide is a novel synthetic peptide that simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual-agonist mechanism positions it at the forefront of type 2 diabetes and obesity research.

In scientific studies, Tirzepatide has been shown to:

• Enhance insulin secretion and sensitivity, improving glycemic control in hyperglycemia models.

• Reduce appetite and food intake, contributing to significant weight loss in metabolic syndrome research.

• Delay gastric emptying, helping modulate postprandial glucose spikes.

• Influence lipid metabolism, with improved HDL/LDL profiles in animal models.

Its combined incretin action delivers superior metabolic effects compared to GLP-1 agonists alone, making it a powerful compound for multifactorial metabolic disorder studies.

• Purity: >99% 
• Form: Lyophilised powder
• Storage: Store dry at -20°C; protect from light
• Solubility: Bacteriostatic water, sterile water, or suitable laboratory solvents
• Storage reconstituted: Store refrigerated (2-8°C)